Cargando…

Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma

Detalles Bibliográficos
Autores principales:	Kaulen, Leon D, Gumbinger, Christoph, Hinz, Felix, Kessler, Tobias, Winkler, Frank, Bendszus, Martin, Sahm, Felix, Wick, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092640/ https://www.ncbi.nlm.nih.gov/pubmed/35571985 http://dx.doi.org/10.1093/noajnl/vdac051

Ejemplares similares

Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas
por: Kaulen, Leon D., et al.
Publicado: (2023)

Primary intraventricular central nervous system lymphoma in an immunocompetent patient
por: Suri, Vinit, et al.
Publicado: (2015)

Intraventricular Primary Central Nervous System Lymphoma Mimicking Ventriculitis
por: Hirato, Tetsuya, et al.
Publicado: (2020)

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
por: Kessler, Tobias, et al.
Publicado: (2023)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Unusual relapse of primary central nervous system lymphoma
por: Igala, Marielle
Publicado: (2016)

Primary cardiac lymphoma with central nervous system relapse
por: van Rooijen, Cleo R., et al.
Publicado: (2017)

Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma
por: Leone, Riccardo, et al.
Publicado: (2023)

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
por: DeVos, Sarah L., et al.
Publicado: (2013)

A Rare Case of Isolated Intraventricular Primary Central Nervous System Lymphoma in an 85-Year-Old Man
por: Khanna, Gaurav, et al.
Publicado: (2021)

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
por: Kickingereder, Philipp, et al.
Publicado: (2015)

Relapsed Primary Central Nervous System Lymphoma: Current Advances
por: Tao, Kaiyan, et al.
Publicado: (2021)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2015)

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017)

Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab
por: Šalaševičius, Lukas, et al.
Publicado: (2020)

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma
por: Chihara, Dai, et al.
Publicado: (2018)

Central Nervous System Progression/Relapse in Mature T- and NK-Cell Lymphomas
por: Bhansali, Rahul S., et al.
Publicado: (2023)

How to use and assess qualitative research methods
por: Busetto, Loraine, et al.
Publicado: (2020)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes
por: Kessler, Tobias, et al.
Publicado: (2020)

Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma
por: Jung, Erik, et al.
Publicado: (2021)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Unusual Relapse of Primary Central Nervous System Lymphoma at Site of Lumbar Puncture
por: Ahmed, Zartaj, et al.
Publicado: (2014)

Central Nervous System Toxoplasmosis in Relapsed Hodgkin’s Lymphoma: A Case Report
por: Abolghasemi, Hassan, et al.
Publicado: (2016)

Late Central Nervous System Relapse in a Patient with Maxillary Sinus Lymphoma
por: Kewan, Tariq, et al.
Publicado: (2018)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023)

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
por: Hodkinson, Brendan P., et al.
Publicado: (2020)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

Extranodal NK/T-Cell Lymphoma Occurring Primarily in the Eyes and with Central Nervous System Relapse
por: Wei, Chong, et al.
Publicado: (2021)

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
por: Nepal, Gaurav, et al.
Publicado: (2022)

Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2): A follow‐up study
por: Doubrovinskaia, Sofia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gkhd96jj0qf7ug105lsqgnrgnv